These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26595826)

  • 1. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease.
    Papp KV; Mormino EC; Amariglio RE; Munro C; Dagley A; Schultz AP; Johnson KA; Sperling RA; Rentz DM
    Neuropsychology; 2016 Jul; 30(5):624-30. PubMed ID: 26595826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.
    Papp KV; Rentz DM; Orlovsky I; Sperling RA; Mormino EC
    Alzheimers Dement (N Y); 2017 Nov; 3(4):668-677. PubMed ID: 29264389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cued memory decline in biomarker-defined preclinical Alzheimer disease.
    Papp KV; Rentz DM; Mormino EC; Schultz AP; Amariglio RE; Quiroz Y; Johnson KA; Sperling RA
    Neurology; 2017 Apr; 88(15):1431-1438. PubMed ID: 28283594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 6. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
    Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
    Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
    Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
    Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lexical factors and cerebral regions influencing verbal fluency performance in MCI.
    Clark DG; Wadley VG; Kapur P; DeRamus TP; Singletary B; Nicholas AP; Blanton PD; Lokken K; Deshpande H; Marson D; Deutsch G
    Neuropsychologia; 2014 Feb; 54():98-111. PubMed ID: 24384308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional network integrity presages cognitive decline in preclinical Alzheimer disease.
    Buckley RF; Schultz AP; Hedden T; Papp KV; Hanseeuw BJ; Marshall G; Sepulcre J; Smith EE; Rentz DM; Johnson KA; Sperling RA; Chhatwal JP
    Neurology; 2017 Jul; 89(1):29-37. PubMed ID: 28592457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Amyloid-β on Cognitive Decline After Stroke/Transient Ischemic Attack: Three-Year Longitudinal Study.
    Liu W; Wong A; Au L; Yang J; Wang Z; Leung EY; Chen S; Ho CL; Mok VC
    Stroke; 2015 Nov; 46(11):3074-80. PubMed ID: 26382174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease.
    Ho JK; Nation DA;
    J Int Neuropsychol Soc; 2018 Aug; 24(7):693-702. PubMed ID: 29706146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep moderates the relationship between amyloid beta and memory recall.
    Wilckens KA; Tudorascu DL; Snitz BE; Price JC; Aizenstein HJ; Lopez OL; Erickson KI; Lopresti BJ; Laymon CM; Minhas D; Mathis CA; Buysse DJ; Klunk WE; Cohen AD
    Neurobiol Aging; 2018 Nov; 71():142-148. PubMed ID: 30138767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease.
    Mueller KD; Koscik RL; Du L; Bruno D; Jonaitis EM; Koscik AZ; Christian BT; Betthauser TJ; Chin NA; Hermann BP; Johnson SC
    Cortex; 2020 Oct; 131():137-150. PubMed ID: 32861209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Oh H; Madison C; Baker S; Rabinovici G; Jagust W
    Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.